 WATERTOWN, Mass., June 30, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public offering of 4,755,000 shares of its common stock at a public offering price of 47.00 per share. All shares are being offered by Kymera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be 223.5 million. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 713,250 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on July 6, 2021, subject to the satisfaction of customary closing conditions. 